A Powerful Choice
For Patients with R/R MZL
Adults with previously treated MZL achieved high partial and complete response rates with sustained results regardless of disease subtype
Deep and sustained responses
Regardless of MZL subtype1
20% of ALL PATIENTS
achieved a CR ACROSS BOTH STUDIES1
Median follow-up time was 15.7 months for
MAGNOLIA (Study 214) and 35.2 months for Study 003.2
Sustained Results1
Median follow-up time was 15.7 months for
MAGNOLIA (Study 214) and 35.2 months for Study 003.2
*55 patients were assessed by PET scan, with the remainder assessed by CT scan.
†Two patients in MAGNOLIA (Study 214, N=68) were not evaluable for efficacy due to central confirmation of MZL transformation to diffuse large B-cell lymphoma.
The efficacy of BRUKINSA was assessed in 2 clinical trials that included a total of 88 adult patients with MZL who received at least 1 prior therapy. Study BGB-3111-214 MAGNOLIA (Study 214): N=68,† Phase 2, open-label, multicenter, single-arm trial; PET scans were required for response assessment. Study BGB-3111-AU-003 (Study 003): N=20, Phase 1/2, open-label, multicenter, single-arm trial; PET scans were not required for response assessment and the majority of patients were assessed mostly using CT scans.
CI=confidence interval; CR=complete response; CT=computed tomography; DOR=duration of response; MZL=marginal zone lymphoma; NE=not estimable; ORR=overall response rate; PET=positron emission tomography; PR=partial response rate; R/R=relapsed/refractory.
POWERFUL RESPONSES REGARDLESS
OF MZL SUBTYPE‡§1-3
In MAGNOLIA (Study 214), 4 patients had unknown subtype.
Rapid disease control1
Median time to response
Median follow-up time was 15.7 months for
MAGNOLIA (Study 214) and 35.2 months for Study 003.2
‡Exploratory analysis.
§In MAGNOLIA (Study 214), PET scans were required for response assessment. In Study 003, PET scans were not required for response assessment and the majority of patients were assessed mostly using CT scans.
¶One patient from MAGNOLIA (Study 214) with nodal disease was readjudicated by the FDA from a PR response to SD, changing ORR to 72%, PR to 52%, and SD to 24%.2
#Two patients in MAGNOLIA (Study 214) were not evaluable for efficacy due to central confirmation of MZL transformation to diffuse large
CI=confidence interval; CR=complete response; MZL=marginal zone lymphoma; ORR=overall response rate; PR=partial response rate; SD=stable disease.
